Cover storyCPV theory is well understood, but literature shows execution is uneven, here's what real-world data reveals about running Stage 3 well.
Teva bids $57.5M upfront for BioXcel's dexmedetomidine sublingual film via Section 363 bankruptcy auction, with up to $125M total consideration.
Celularity's Florham Park cGMP site will manufacture Dezawa MuseCells and derived products for MCI, with $300M in projected purchases over five years.
FDA links 30 adverse events to IV glutathione compounded from dietary supplement grade ingredient sourced from Medisca, citing endotoxin risk and supplier qualification failures.
FDA extends use dates on 14 injectable lots from Hospira and Baxter; no relabeling required, but disposal obligations apply when replacements arrive.
Latest edition
Interview20260622153015.png&w=1920&q=75&dpl=dpl_4mCM4LkTaakSXHxN4EsrYb1NmZRR)
Interview
Interview
Podcast
Sep 28
Nov 18
Feb 03From native content to event partnerships, we help brands earn the attention of a hard-to-reach, senior audience — without breaking the reading experience.
See partnership options →Explore expert-led guides crafted for pharma professionals. Log in to download and stay ahead.
Join thousands of pharma professionals getting our sharpest reporting, briefings and guides — free.
20260804110923.webp&w=1920&q=75&dpl=dpl_4mCM4LkTaakSXHxN4EsrYb1NmZRR)
